4506 — Sumitomo Pharma Co Balance Sheet
0.000.00%
- ¥1tn
- ¥1tn
- ¥399bn
- 56
- 47
- 100
- 80
Annual balance sheet for Sumitomo Pharma Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 223,178 | 238,580 | 163,652 | 36,132 | 39,956 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 136,060 | 151,500 | 98,630 | 97,239 | 77,726 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 459,795 | 499,521 | 381,860 | 269,569 | 253,168 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 64,966 | 64,091 | 58,909 | 57,895 | 46,648 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,308,127 | 1,308,007 | 1,134,742 | 907,506 | 742,604 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 278,147 | 278,373 | 372,694 | 515,474 | 240,603 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 727,557 | 700,119 | 727,993 | 751,443 | 573,125 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 580,570 | 607,888 | 406,749 | 156,063 | 169,479 |
| Total Liabilities & Shareholders' Equity | 1,308,127 | 1,308,007 | 1,134,742 | 907,506 | 742,604 |
| Total Common Shares Outstanding |